• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Changes in coverage among non-elderly adults with chronic diseases following Affordable Care Act implementation
by John D. Goodson, Sara Shahbazi, Zirui Song ImportanceChanges in insurance coverage after the Affordable Care Act (ACA) among non-elderly adults with self-reported chronic conditions across income categories have not been described. ObjectiveTo examine changes in insurance coverage after the ACA among non-elderly adults with chronic conditions across income categories, by geographic region. DesignWe compared self-reported access to health insurance pre-ACA (2010-2013) and post-ACA (2014-2017) for individuals 18-64 years of age with ≥ 2 chronic conditions, including hypertension, heart disease/stroke, emphysema, diabete...
Source: PLoS One - November 30, 2022 Category: Biomedical Science Authors: John D. Goodson Source Type: research

Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study
ConclusionThis population-based retrospective cohort study has shown that Celecoxib and Etoricoxib reduce the risk of ischemic stroke in patients with RA in a dose- and time-dependent manner.
Source: Frontiers in Neurology - October 20, 2022 Category: Neurology Source Type: research

Prevalence of chronic diseases and ownership of health insurance among the elderly: comparison of data from the Brazilian National Health Survey of 2013 and 2019
This study aimed to estimate and compare the prevalence of chronic diseases among the elderly, according to the possession of a health plan in 2013 and 2019. This is a population-based cross-sectional study with data from elderly people (age ≥ 60 years) from the Brazilian National Health Survey (2013: n = 11,177; 2019: n = 22,728). The prevalence of self-reported chronic diseases and adjusted prevalence ratios were estimated, according to health plan ownership (medical and/or dental) and by year. In the period, increased prevalence was observed for hypertension (PR = 1.11; 95%CI: 1.06-1.16), diabetes (PR = 1.12; 95%CI: 1...
Source: Cadernos de Saude Publica - September 14, 2022 Category: International Medicine & Public Health Authors: Priscila Maria Stolses Bergamo Francisco Aldiane Gomes de Macedo Bacurau Daniela de Assump ção Source Type: research

Hypothyroidism risk associated with rheumatoid arthritis: A population-based retrospective cohort study
Studies on the thyroid disease risk in patients with rheumatoid arthritis (RA) associated with comorbidities are limited. This population-based retrospective cohort study investigated the hypothyroidism risk in patients with RA and the role of comorbidities. We used Taiwan National Health Insurance Research Database to identify 16,714 RA patients newly diagnosed in 2000 to 2008 and 66,856 control persons without RA, frequency matched by sex, age, and index year. Incidence and the RA group to controls hazard ratio of hypothyroidism were estimated. The hypothyroidism incidence was 1.74-fold higher in the RA group than ...
Source: Medicine - January 7, 2022 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pages: 1  2  3  4